浙江万安科技股份有限公司 2025 年员工持股计划（草案）摘要 证券简称：万安科技 证券代码：002590 浙江万安科技股份有限公司 浙江万安科技股份有限公司 2025 年员工持股计划（草案）摘要 特别提示 安科技股份有限公司依据《中华人民共和国公司法》《中华人民共和国证券法》 《关于上市公司实施员工持股计划试点的指导意见》《深圳证券交易所上市公司 自律监管指引第 1 号——主板上市公司规范运作》等有关法律、行政法规、规章、 规范性文件和《浙江万安科技股份有限公司章程》的规定制定。 派、强行分配等强制员工参加本员工持股计划的情形。 （草案）摘要 浙江万安科技股份有限公司 2025 年员工持股计划（草案）摘要 声 明 本公司及董事会全体成员保证本员工持股计划及其摘要不存在虚假记载、误 导性陈述或重大遗漏。 浙江万安科技股份有限公司 2025 年员工持股计划（草案）摘要 风险提示 能否获得公司股东大会批准，存在不确定性。 等属初步结果，能否完成实施，存在不确定性。 认购资金不足，本员工持股计划存在低于预计规模的风险。 意投资风险。 司董事会对本员工持股计划进行审议且无异议后，公司将发出召开股东大会的通 知，提请股 ...

Core Viewpoint - The company has developed a draft for the 2025 Employee Stock Ownership Plan (ESOP) in compliance with relevant laws and regulations, aiming to enhance employee engagement and align interests between employees and shareholders [1][2] Compliance with Regulations - The company confirms that there are no prohibitive circumstances under the relevant guidelines and regulations for implementing the employee stock ownership plan [1] - The content of the employee stock ownership plan aligns with the guidelines and does not harm the interests of the company or its shareholders [1] - The decision-making process for the employee stock ownership plan was legal and effective, with related directors abstaining from voting to avoid conflicts of interest [1] Eligibility and Financial Support - The proposed participants in the employee stock ownership plan meet the eligibility criteria set forth in the relevant guidelines [1] - The company does not plan to provide loans, guarantees, or any other financial assistance to the participants of the employee stock ownership plan [1] Benefits of the Plan - The implementation of the employee stock ownership plan is expected to establish a mechanism for shared interests between employees and shareholders, enhancing employee cohesion and the company's competitiveness [1] - The plan aims to create a community of interests between management and shareholders, improving management efficiency and the responsibility of operators, which is beneficial for the company's sustainable development and strategic goals [1]

Group 1 - The company achieved operating revenue of 1.121 billion yuan and a net profit attributable to shareholders of 368 million yuan in the first half of 2025, representing a year-on-year growth of 17.17% [2][3] - The core business of the company, the power equipment segment, showed steady growth with revenue increasing by 127 million yuan, or 15.29% year-on-year [3] - The international revenue exceeded 200 million yuan, with a growth rate of over 40%, primarily driven by the rapid growth of overseas sales in the CNC equipment business [4] Group 2 - The company’s cash flow situation is stable, with fluctuations in operating cash flow aligning with changes in revenue structure, and there are no signs of cash flow pressure [3] - The company’s power engineering business revenue declined due to project settlement timing, impacting both operating costs and cash flow [3][27] - The CNC equipment business showed good performance in the first half of the year, with revenue growth of approximately 33 million yuan, although its contribution to overall revenue and profit remains low [5] Group 3 - The company is focusing on expanding its overseas market presence, particularly in Europe and Asia, where significant growth has been observed [7][13] - The company has established a factory in Indonesia, which has contributed to noticeable growth in the Indonesian market [14] - The company plans to invest in upgrading facilities to support the CNC equipment business and may consider local investments in markets like Saudi Arabia if sufficient orders are secured [17][36] Group 4 - The company’s strategy emphasizes localizing operations in overseas markets, which has proven effective in driving growth [8][20] - The company has not observed significant changes in transformer demand in overseas markets, indicating stable demand conditions [19] - The company aims to maintain a stable gross margin for its products, despite various influencing factors [35] Group 5 - The company has set ambitious targets for net profit growth over the next three years, although achieving these targets may be challenging [33] - The company’s domestic market performance has shown a 5% year-on-year growth, with stable growth in the grid-related segment [22][24] - The company is cautious about projecting future revenue growth due to the short order delivery cycle and the uncertainty in project timelines [31]

证券研究报告 | 公司动态点评 2025 年 08 月 13 日 塔牌集团（002233.SZ） 量增本降助力业绩高增，回购+高股息展现投资价值 作者 分析师 花 江月 执业证书编号：S1070522100002 | 财务指标 | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业收入（百万元） | 5,535 | 4,278 | 4,413 | 4,532 | 4,769 | | 增长率 yoy（%） | -8.3 | -22.7 | 3.2 | 2.7 | 5.2 | | 归母净利润（百万元） | 742 | 538 | 676 | 742 | 802 | | 增长率 yoy（%） | 178.5 | -27.5 | 25.7 | 9.7 | 8.1 | | ROE（%） | 6.2 | 4.6 | 5.7 | 6.0 | 6.4 | | EPS 最新摊薄（元） | 0.62 | 0.45 | 0.57 | 0.62 | 0.67 | | P/E（倍） | 13.7 | 18.8 | 15.0 ...

Core Viewpoint - Wuhan Keqian Biological Co., Ltd. plans to sign a cooperative research and development agreement with Huazhong Agricultural University, involving four vaccine projects, with a total payment of 4.9 million RMB [2][4][67]. Group 1: Overview of Related Transactions - The company has obtained cooperation for the development of four projects: "Canine Distemper, Canine Parainfluenza, Canine Adenovirus and Canine Parvovirus Quadrivalent Live Vaccine - Inactivated Canine Coronavirus Vaccine," "Porcine Gata Virus Inactivated Vaccine," "Porcine Proliferative Enteropathy Blocking ELISA Antibody Test Kit," and "NADC30-like Porcine Reproductive and Respiratory Syndrome Live Vaccine (GX2024 Strain)" [2][4][67]. - The total payment to Huazhong Agricultural University for these projects is 4.9 million RMB, with specific allocations of 1.5 million RMB, 2 million RMB, 400,000 RMB, and 1 million RMB for each project respectively [4][67]. - The transaction constitutes a related party transaction but does not qualify as a major asset restructuring under relevant regulations [2][4][67]. Group 2: Necessity and Impact of Related Transactions - The cooperative research aims to enhance the company's product portfolio and market competitiveness, although the success of the projects and their market introduction remain uncertain [67]. - The pricing and process of the transaction comply with legal regulations and do not harm the interests of the company or minority shareholders [67]. Group 3: Approval Procedures for Related Transactions - The board of directors and the supervisory board have approved the agreement, with related directors abstaining from voting [68][69]. - Independent directors have expressed that the agreement will enhance the company's core competitiveness in the biological products sector and that the transaction process is legal and fair [71][72]. Group 4: Research and Development Agreement Details - The agreement includes provisions for the rights and obligations of both parties, including the management of research funds and the ownership of intellectual property generated from the projects [8][37][52]. - The agreement is valid for 10 years, with provisions for extension and termination under certain conditions [20][36][66].

登录新浪财经APP 搜索【信披】查看更多考评等级 本公司及董事会全体成员保证信息披露内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 丽珠医药集团股份有限公司（以下简称"公司"或"丽珠集团"）中长期事业合伙人持股计划之第二期员工 持股计划（以下简称"本期持股计划"）锁定期于2025年8月12日届满。根据《关于上市公司实施员工持 股计划试点的指导意见》及《深圳证券交易所上市公司自律监管指引第1号一主板上市公司规范运作》 等相关规定，现将本期持股计划相关情况公告如下： 一、本持股计划的基本情况和锁定期 公司于2022年5月20日召开了公司2021年度股东大会，审议通过了《关于公司〈中长期事业合伙人持股 计划之第二期持股计划（草案）〉及其摘要的议案》等相关议案，于2022年7月8日召开了公司2022年第 一次临时股东大会，审议通过了《关于修订公司〈中长期事业合伙人持股计划之第二期持股计划〉及其 摘要的议案》等相关议案，同意公司实施中长期事业合伙人持股计划之第二期持股计划并授权公司董事 会办理相关事宜。有关详情及进展情况请见公司于2022年5月21日、2022年7月9日及2022年8月11日在巨 潮资讯网 ...

证券代码：002909 证券简称：集泰股份 公告编号：2025-068 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记载、误导性陈述或重大遗 漏。 根据中国证券监督管理委员会《上市公司募集资金监管规则》、深圳证券交易所颁布的《深圳证券交易 所上市公司自律监管指引第1号——主板上市公司规范运作》及相关公告格式规定，广州集泰化工股份 有限公司（以下简称"公司"或"本公司"）2025年半年度（以下简称"本报告期"）募集资金存放与使用情 况报告如下： 登录新浪财经APP 搜索【信披】查看更多考评等级 2、2022年向特定对象发行A股股票 本公司于2023年7月获得中国证券监督管理委员会出具的《关于同意广州集泰化工股份有限公司向特定 对象发行股票注册的批复》证监许可字[2023]1561号文同意，本公司向特定对象发行26,092,671股人民 币普通股（A 股），每股面值为人民币1.00元，每股发行价格为人民币6.50元，实际募集资金总额为人 民币169,602,361.50元，扣除保荐承销费用人民币12,400,000.00元（含增值税）后（应支付保荐承销费用 人民币15,000,000.00元 ...

Core Viewpoint - The company has not met the performance assessment indicators for the third unlocking period of its 2022 employee stock ownership plan, resulting in no shares being unlocked for this period [8][12][26]. Group 1: Employee Stock Ownership Plan Approval and Implementation - The employee stock ownership plan was approved by the company's board of directors on August 23, 2022, and subsequently by the shareholders on September 9, 2022 [6][27]. - The plan involves a total of 2,950,060 shares, which were transferred to the employee stock ownership plan at a price of 7.50 yuan per share, accounting for 0.51% of the company's total share capital [29]. Group 2: Locking Period and Performance Assessment - The locking period for the employee stock ownership plan is set for a maximum of 36 months, with shares being unlocked in three phases: 30% after 12 months, 35% after 24 months, and 35% after 36 months [9][30]. - The company’s performance assessment for the third unlocking period was based on company-level and individual-level indicators, which were not met, leading to 1,032,521 shares being locked and not unlocked [11][31]. Group 3: Consequences of Not Meeting Performance Indicators - Due to the failure to meet the performance indicators, the shares will be reclaimed by the management committee of the employee stock ownership plan and may be sold to return the investment amount to the holders [12][31]. - If any profits arise from the sale of the shares, those profits will belong to the company [12][31]. Group 4: Future Considerations - The employee stock ownership plan has a total duration of 48 months, and if not extended, it will terminate upon reaching the end of this period [33]. - The company will continue to monitor the implementation of the employee stock ownership plan and fulfill its disclosure obligations as required by law [35].

Group 1 - The first meeting of the 2025 second employee stock ownership plan was held on August 9, 2025, with 99 participants representing 12,931,462 shares [2][3] - The meeting unanimously approved the establishment of a management committee for the employee stock ownership plan and elected members, ensuring no conflicts of interest with major shareholders or executives [3] - The management committee is authorized to handle various matters related to the employee stock ownership plan until its completion, including convening meetings, exercising shareholder rights, and managing daily operations [4][5] Group 2 - The management committee's responsibilities include decision-making on share transfers, qualification cancellations, and signing relevant agreements on behalf of the plan [5] - All resolutions passed during the meeting received 100% approval from the participating shareholders, indicating strong support for the plan [3][4] - The management committee's chairperson was elected on the same day, with a term lasting until the plan's completion [3]

证券代码：002233 证券简称：塔牌集团 公告编号：2025-038 广东塔牌集团股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 特别提示： 式回购公司部分股份，本次回购股份资金总额为不超过10,000万元（含）且不少于5,000万元（含）， 回购价格不超过10元/股，回购的期限为自董事会审议通过回购方案之日起6个月内。回购的股 份拟用于公司实施员工持股计划。 本次回购方案在董事会审批权限内，无需提交股东大会审议。 导致本次回购无法实施或只能部分实施的风险。本次回购方案不代表公司将在二级市场回购公 司股份的承诺，公司将在回购期限内根据市场情况择机做出回购决策并予以实施，敬请投资者 注意投资风险。 一、回购方案的主要内容 （一）回购股份的目的和用途 本次回购的种类为境内上市人民币普通股（A 股）。 （三）回购的方式 本次回购拟采用集中竞价的方式。 （四）回购股份的价格区间 本次回购价格不超过 10 元/股（含），回购价格上限未超过董事会通过本回购股份决议前 三十个交易日公司股票交易均价（按照董事会通过本回购股份决议前三十个交易日的股票交易 总额除 ...